Prince Pharmaceutical Co., Ltd.(TW:6935)
NT$28.00-0.20 (-0.71%)
TW:6935
Prince Pharmaceutical Co., Ltd. financials statements
NT$28.00
At close:-0.20 (-0.71%)
Prince Pharmaceutical Co., Ltd. (6935) Income Statement
Prince Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Prince Pharmaceutical Co., Ltd.'s total revenue was NT$616.64M, an increase of 81.46% from the same quarter last year. In Q2, Prince Pharmaceutical Co., Ltd.'s net income was NT$51.57M. See Prince Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| NT$ 1.06B | NT$ 690.02M | NT$ 753.33M | NT$ 712.53M | NT$ 441.08M | |
| NT$ 222.55M | NT$ 74.28M | NT$ 153.09M | NT$ 205.79M | NT$ 125.49M | |
| NT$ 111.67M | NT$ 123.63M | NT$ 127.41M | NT$ 137.95M | NT$ 126.58M | |
| Depreciation and Amortization | NT$ 61.61M | NT$ 62.49M | NT$ 58.56M | NT$ 52.35M | NT$ 46.22M |
| NT$ 175.94M | NT$ 20.68M | NT$ 88.19M | NT$ 125.58M | NT$ 43.47M | |
| NT$ 110.88M | NT$ -49.35M | NT$ 25.68M | NT$ 67.85M | NT$ -1.11M | |
| NT$ -6.14M | NT$ -2.73M | NT$ -6.51M | NT$ -3.65M | NT$ -9.21M | |
| NT$ 104.74M | NT$ -52.08M | NT$ 19.17M | NT$ 64.20M | NT$ -10.31M | |
| NT$ 96.32M | NT$ -53.54M | NT$ 15.31M | NT$ 51.55M | NT$ -8.30M | |
| Per Share Metrics | |||||
| Basic EPS | NT$ 2.63 | NT$ -1.46 | NT$ 0.43 | NT$ 1.55 | NT$ -0.25 |
| Diluted EPS | NT$ 2.63 | NT$ -1.46 | NT$ 0.42 | NT$ 1.55 | NT$ -0.25 |
| Weighted Average Shares Outstanding | 36.65M | 36.55M | 35.60M | 33.19M | 33.19M |
| Weighted Average Shares Outstanding (Diluted) | 36.65M | 36.55M | 36.45M | 33.33M | 33.19M |
Currency in TWD
